Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Issues
2018
August 2018, Vol 9, No 2
August 2018, Vol 9, No 2 | Payers’ Perspectives In Oncology: ASCO
Cost of Treating Colorectal Cancer in the United States Double That of Canada, with No Survival Benefitc
By
Phoebe Starr
Economics & Value
,
Value-Based Care
August 2018, Vol 9, No 2 | Payers’ Perspectives In Oncology: ASCO
Chicago, IL—Healthcare costs in the United States have spiraled out of control, and polls show that single-payer healthcare is gaining traction.
Read Article
PARP Inhibitors Least Cost-Effective as Maintenance Therapy in Advanced Ovarian Cancer
By
Chase Doyle
Economics & Value
,
Value-Based Care
August 2018, Vol 9, No 2 | Payers’ Perspectives In Oncology: ASCO
Read Article
Next-Generation Sequencing More Cost-Effective and Faster Than Single-Gene Testing
By
Phoebe Starr
Economics & Value
,
Value-Based Care
August 2018, Vol 9, No 2 | Payers’ Perspectives In Oncology: ASCO
“NGS decreased the cost of testing, identified the highest percentage of targetable genetic alterations, and had the fastest turnaround,” reported Nathan A. Pennell, MD, PhD.
Read Article
NCCN Drug Affordability Ratings Miss the Mark in Lung Cancer
By
Wayne Kuznar
Lung Cancer
,
Solid Tumors
,
Personalized Medicine
August 2018, Vol 9, No 2 | Payers’ Perspectives In Oncology: ASCO
Read Article
LOXO-292 Highly Effective in RET-Positive Cancers
By
Chase Doyle
Emerging Therapies
,
Personalized Medicine
August 2018, Vol 9, No 2 | Payers’ Perspectives In Oncology: ASCO
“These promising results underscore the importance of screening for these alterations in the clinic. The activity of LOXO-292 is durable, with over 90% of patients still on treatment as of the data cutoff,” said Alexander E. Drilon, MD.
Read Article
Ivosidenib a New Standard of Care for Relapsed or Refractory AML with IDH1 Mutation
By
Phoebe Starr
Emerging Therapies
,
Personalized Medicine
August 2018, Vol 9, No 2 | Payers’ Perspectives In Oncology: ASCO
Read Article
Cell-Free DNA Assays Could Result in a New Blood Test for Early Detection of Cancer
By
Wayne Kuznar
Genomic Testing
August 2018, Vol 9, No 2 | Payers’ Perspectives In Oncology: ASCO
“These results support the promise of using cfDNA-based assays to develop an early cancer detection test with high specificity,” says Geoffrey R. Oxnard, MD.
Read Article
IMPACT: Matching Treatment and Molecular Testing Extends Survival in Advanced Cancer
By
Wayne Kuznar
Genomic Testing
August 2018, Vol 9, No 2 | Payers’ Perspectives In Oncology: ASCO
“This is the first and largest study that shows that matching treatments to genetic mutations in tumors in patients with advanced cancer improves survival,” according to Catherine S. Magid Diefenbach, MD.
Read Article
Investigational CAR T-Cell Therapy, bb2121, Shows Durable Responses in Relapsed or Refractory Multiple Myeloma
By
Wayne Kuznar
Immunotherapy
,
Multiple Myeloma
,
Hematologic Malignancies
,
Personalized Medicine
August 2018, Vol 9, No 2 | Payers’ Perspectives In Oncology: ASCO
Read Article
CAR T-Cell Therapy Yields Impressive Responses in Aggressive Non-Hodgkin Lymphoma
By
Chase Doyle
Immunotherapy
,
Personalized Medicine
August 2018, Vol 9, No 2 | Payers’ Perspectives In Oncology: ASCO
Chicago, IL—Lisocabtagene maraleucel (liso-cel), an investigational CD19-directed chimeric antigen receptor (CAR) T-cell therapy, has induced durable responses in high-risk patients with aggressive relapsed or refractory non-Hodgkin lymphoma (NHL), according to data presented at ASCO 2018.
Read Article
Page 2 of 3
1
2
3
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Medication Assurance Programs, as Deceiving and Harmful as Alternate Funding Programs
Dawn Holcombe, MBA, FACMPE, ACHE
2.
Addressing Challenges to Adoption of Value-Based Agreements
Phoebe Starr
3.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma